Cardiovascular safety of etoricoxib
https://doi.org/10.14412/1996-7012-2011-686
Abstract
Meticulous attention is paid to the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs), the so-called selective cyclooxy-genase 2 (COX-2) inhibitors in particular. The author considers precisely this matter in case of Russia's recent NSAID etoricoxib that has been tested along with other most studied medications from this group, by applying one of the latest meta-analyses. The EULAR recommendations to use NSAIDs are given.
Review
For citations:
Barskova VG, Barskova VG. Cardiovascular safety of etoricoxib. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2011;5(3):52-57. (In Russ.) https://doi.org/10.14412/1996-7012-2011-686
Views:
1293
Email this article 